Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Deals

Berry Genomics Collaborates with Beijing Children’s Hospital on Newborn Birth Defects Screening Project

Fineline Cube Apr 17, 2025

China-based genomics testing company Berry Genomics (SHE: 000710) has entered into a project achievement translation...

Policy / Regulatory

Trump Orders HHS to Reduce Drug Prices, Revamp Medicare Negotiation Program

Fineline Cube Apr 17, 2025

President Donald Trump issued a new Executive Order aimed at reducing drug prices for American...

Company Drug

Galderma Launches Sculptra in China as First Regenerative Biostimulator

Fineline Cube Apr 16, 2025

Switzerland-based skin care specialist Galderma officially launched Sculptra in China this week, marking the first...

Company Drug

Easton Pharma’s EP-9001A Shows Promising Results in Phase Ib for Bone Metastasis Cancer Pain

Fineline Cube Apr 16, 2025

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced preliminary statistical analysis results from the...

Company Medical Device

Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System

Fineline Cube Apr 16, 2025

US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received...

Company Drug

InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers

Fineline Cube Apr 16, 2025

Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China’s Center for...

Policy / Regulatory

NHC Releases Standardized Family Doctor Service Packages for Key Demographic Groups

Fineline Cube Apr 16, 2025

The National Health Commission (NHC) has issued the “List of Basic Service Packages for Family...

Company Deals Medical Device

Kosell Medtech Partners with Wenzhou Medical University on K-Sheath System

Fineline Cube Apr 16, 2025

China-based Kossel Medtech (Suzhou) Co., Ltd., a vascular interventional medical device platform company, has entered...

Company Drug

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies

Fineline Cube Apr 16, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four...

Company Drug

Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529

Fineline Cube Apr 16, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received clinical...

Company Drug

AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients

Fineline Cube Apr 16, 2025

Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for...

Company Deals

Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech

Fineline Cube Apr 16, 2025

Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...

Company Drug Policy / Regulatory

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security

Fineline Cube Apr 16, 2025

The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...

Company

Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech

Fineline Cube Apr 16, 2025

US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...

Company Drug

BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study

Fineline Cube Apr 15, 2025

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...

Company Drug

Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males

Fineline Cube Apr 15, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has initiated a Phase III...

Company Drug

Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer’s Disease

Fineline Cube Apr 15, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors

Fineline Cube Apr 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced clearance from the National Medical...

Company Drug

Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case

Fineline Cube Apr 15, 2025

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...

Company Drug

Roche’s Columvi Approved by EC for Relapsed DLBCL Treatment in Europe

Fineline Cube Apr 15, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing...

Posts pagination

1 … 178 179 180 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.